What Happened? Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 7.5% in the morning session after ...

Shares of Charles River Laboratories International Inc. advanced 9.06% to $163.36 Tuesday, on what proved to be an all-around ...

Charles River Laboratories is poised to announce its second-quarter results next month, and analysts predict a double-digit ...

This was the stock's third consecutive day of losses.

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and ...

Charles River Laboratories' share price has declined over 50% from its 2021 peak, presenting a potential buying opportunity for investors. The CRO company is facing headwinds from COVID's overhang ...

Charles River Labs seeks support for merger with WuXi Facing opposition over its $1.6 billion merger with WuXi Pharmatech, Charles River Laboratories International is wooing support for the deal ...

What's happening. On May 6, Elliott and Charles River Laboratories entered into a cooperation agreement in which four incumbent directors won't seek re-election and the following four individuals ...

charles river laboratories and wuxi pharmatech to combine, creating the first global cro offering fully integrated early-stage drug development services to clients worldwide --$1.6 billion.

This was the stock's second consecutive day of losses.